KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Capital BDC (CCAP) Liabilities and Shareholders Equity (2021 - 2026)

Crescent Capital BDC filings provide 5 years of Liabilities and Shareholders Equity readings, the most recent being $1.6 billion for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 2.06% to $1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 billion, a 0.36% change, with the full-year FY2025 number at $1.6 billion, down 2.06% from a year prior.
  • Liabilities and Shareholders Equity hit $1.6 billion in Q4 2025 for Crescent Capital BDC, roughly flat from $1.6 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.7 billion in Q2 2024 to a low of $1.3 billion in Q4 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $1.6 billion (2023), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: rose 24.91% in 2023 and later dropped 2.06% in 2025.
  • Crescent Capital BDC's Liabilities and Shareholders Equity stood at $1.3 billion in 2021, then dropped by 1.13% to $1.3 billion in 2022, then rose by 24.91% to $1.6 billion in 2023, then grew by 1.78% to $1.7 billion in 2024, then fell by 2.06% to $1.6 billion in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $1.6 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.